Oxurion

Oxurion ROCE

The Return on Capital Employed (ROCE) of Oxurion (OXUR.BR) as of Oct 19, 2026 is -3.45 %. In the previous year, Return on Capital Employed (ROCE) was 90.87 % — a change of -103.80% (lower).

ROCE

-3.45 %

YoY

-103.80%

Last updated:

In 2024, Oxurion's return on capital employed (ROCE) was -3.45 %, a -103.80% increase from the 90.87 % ROCE in the previous year.

The Oxurion ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2017
17.54 EUR
Jan 1, 2018
-37.41 EUR
Jan 1, 2019
-66.37 EUR
Jan 1, 2020
-113.17 EUR
Jan 1, 2021
2,538.78 EUR
Jan 1, 2022
478.86 EUR
Jan 1, 2023
90.87 EUR
Jan 1, 2024
-3.45 EUR
The Oxurion ROCE history
YEARROCEYoY
-3.45 %-103.80%
90.87 %-81.02%
478.86 %-81.14%
2,538.78 %-2,343.42%
-113.17 %+70.50%
-66.37 %+77.41%
-37.41 %-313.27%
17.54 %-156.25%
-31.19 %+36.15%
-22.91 %-9.59%
-25.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Oxurion's Return on Capital Employed (ROCE)

Oxurion's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Oxurion's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Oxurion's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Oxurion’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Oxurion stock

Return on Capital Employed (ROCE) of Oxurion is -3.45 % in 2024.

Return on Capital Employed (ROCE) of Oxurion changed from 90.87 % to -3.45 %, representing a -103.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Oxurion since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Oxurion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Oxurion

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Oxurion